Wraith, David. "Preclinical Efficacy and Phase I Clinical Testing of ATX-MS1467, an Antigen-Specific Immunotherapy for Multiple Sclerosis (P1.189)." Neurology 82.10 Supplement (2014): P1.189. Web. 21 Oct. 2021.